The effect of cost on adherence to prescription medications in Canada. - Wikidata - wikimedia - TriplyDB

The effect of cost on adherence to prescription medications in Canada.

The effect of cost on adherence to prescription medications in Canada.

http://www.wikidata.org/entity/Q35761548

about

How payment scheme affects patients' adherence to medications? A systematic review Universal prescription drug coverage in Canada: Long-promised yet undelivered Canadian list of essential medications: Potential and uncertainties Liste canadienne des médicaments essentiels: Potentiel et incertitudes.Medication access via hospital admission.L’accès aux médicaments par l’hospitalisation Impact of income-based deductibles on drug use and health care utilization among older adults.CETA and pharmaceuticals: impact of the trade agreement between Europe and Canada on the costs of prescription drugs.Estimated cost of universal public coverage of prescription drugs in Canada Herpes zoster vaccine (HZV): utilization and coverage 2009 - 2013, Alberta, Canada Delivering on the promise of Medicare.Persistent medication affordability problems among disabled Medicare beneficiaries after Part D, 2006-2011 Policy versus practice: a community-based qualitative study of the realities of pharmacy services in Nunavut, Canada.Canadian pharmacare: looking back, looking forward.Financial barriers and adverse clinical outcomes among patients with cardiovascular-related chronic diseases: a cohort study.Exploring the impact of financial barriers on secondary prevention of heart disease.Universal drug coverage and socioeconomic disparities in major diabetes outcomes Use of Compassionate Supply of Antiretroviral Drugs to Avoid Treatment Interruptions or Delayed Treatment Initiation among HIV-Positive Patients Living in Ontario: A Retrospective Review.The Impact of Private Insurance Coverage on Prescription Drug Use in Ontario, Canada.Non-adherence in type 2 diabetes: practical considerations for interpreting the literature The potential exploitation of research participants in high income countries who lack access to health care A fresh perspective on comparing the FDA and the CHMP/EMA: approval of antineoplastic tyrosine kinase inhibitors.The road to competitive generic drug prices in Canada.Finding resiliency in the face of financial barriers: Development of a conceptual framework for people with cardiovascular-related chronic disease.Addressing cost-related barriers to prescription drug use in Canada.Cost-related non-adherence to prescribed medicines among older adults: a cross-sectional analysis of a survey in 11 developed countries.Estimated effects of adding universal public coverage of an essential medicines list to existing public drug plans in Canada.Provincial disparities of growth hormone coverage for young adult survivors of paediatric brain tumours across Canada Development of a preliminary essential medicines list for Canada.The effects of catastrophic drug plan deductibles on older women's use of cardiovascular medicines: a retrospective cohort study.Cost-related nonadherence to prescribed medicines among older Canadians in 2014: a cross-sectional analysis of a telephone survey.Real-world factors affecting adherence to insulin therapy in patients with Type 1 or Type 2 diabetes mellitus: a systematic review.Drug adherence of patients with epilepsy in Iran: the effects of the international economic sanctions.Money left on the table: generic drug prices in Canada.Understanding Financial Barriers to Care in Patients With Diabetes.Potential contribution of lifestyle and socioeconomic factors to healthy user bias in antihypertensives and lipid-lowering drugs.Barriers to Prescription Medication Adherence Among Homeless and Vulnerably Housed Adults in Three Canadian Cities.Protocol for a randomised controlled trial evaluating the effects of providing essential medicines at no charge: the Carefully seLected and Easily Accessible at No Charge Medicines (CLEAN Meds) trial.A Better Prescription: Advice for a National Strategy on Pharmaceutical Policy in Canada.Out-of-pocket costs and adherence to antihypertensive agents among older adults covered by the public drug insurance plan in Quebec.

P2860

Q26745601-BDBB51B0-4107-49D5-B0BE-80C02E1D560B Q28069734-08D09C8C-A826-477D-B916-0A14FF6185C9 Q33558488-81FC5131-5272-4C23-AE65-57A59D8BC3D1 Q33558544-D0C9D6CC-DE57-4BC1-B836-5E08DF47DB5B Q33675478-8024803A-9CD4-44B7-ADC6-7EB21B98F796 Q33675487-18CCC3E3-3272-4F2B-A0B1-380104111C72 Q33694182-2FECB499-E295-4D37-BC67-311DFEA145F0 Q33939125-233D6B44-0CE0-42D8-ACCC-511ED1AABF96 Q34467493-D879C233-6F53-4D43-85FA-9A971B859565 Q34875123-8BBD097C-8146-4FBC-9915-FD3117362D7E Q35077070-6401AA79-9156-446B-A6A6-A1F13745E1C0 Q35963348-F5E9C54A-F823-49C9-97D0-0090568122B1 Q36076807-13268854-AB2C-40AB-B241-CDB47C265D8A Q36196926-634C3D09-683B-436A-BA3B-9E40B80BAB24 Q36280399-1CC1F7DC-3266-4E33-A984-C7F43A710010 Q36280419-3C97AE5B-A013-4F94-AEDB-25767A7C32B1 Q36334609-4212EC4F-B3B3-402D-A4BE-4495DB504328 Q36565336-C25A010F-9670-4B13-82A8-9B89A85D8665 Q36565360-3494A149-7787-41F8-B512-170A5BDA2966 Q36669031-15601E9A-2C1F-499A-AA97-3F90C162FFEB Q36806612-EBDA61CD-25A8-4B43-A5CC-D85F85BF5B4B Q37161896-880D6260-93FC-4B27-8E3E-39089E77305E Q37186277-6646CCB4-0B5E-425D-9F49-DB4FDC5FD2CE Q37606129-4B724AE5-0604-4FFC-B937-7129CF9628DD Q37614006-FB68C364-BD96-45F4-A431-FCE2F5A0D5D9 Q37627254-4C2FD91C-E8AD-4333-8046-AF403ECAF268 Q37666110-556F0A06-E400-44AD-BD26-0076E0A5E16C Q37723149-D47DD873-A7CF-4C1E-A77E-396B637F12B1 Q37735852-8294F4DD-3B42-476F-B1E0-48D8E65249A8 Q37735873-AAA213E1-79D2-47E5-9505-89F5ADB47483 Q37735874-4D18E6BB-71EA-47AA-8A31-AF5E8166C92A Q38074481-CF4C374B-D897-4021-880D-090782352D66 Q38600713-9E7E2BD9-C2AA-4D44-83A4-BCAED5916C6C Q38964167-587BB0AF-1A48-470B-BA46-6F20191C3C43 Q39128642-628A7185-91B4-4790-9980-67B088C24A01 Q40100271-D8980528-DFDA-4465-AE0E-89F44A799E8D Q40237513-5F02DEAE-DBCE-48F6-896B-825738D1A69E Q40478455-4E77D012-1F02-4ECA-92E1-E5B03C4E7D74 Q40995361-FF00CDF6-D27A-4E6D-B559-9623440B9503 Q41080901-9FF6CABF-2FBC-41D5-BF2F-3D8F95B64EA2

P2860

The effect of cost on adherence to prescription medications in Canada.

http://www.wikidata.org/entity/Q35761548

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

The effect of cost on adherence to prescription medications in Canada.

@ast

The effect of cost on adherence to prescription medications in Canada.

@en

type

label

The effect of cost on adherence to prescription medications in Canada.

@ast

The effect of cost on adherence to prescription medications in Canada.

@en

prefLabel

The effect of cost on adherence to prescription medications in Canada.

@ast

The effect of cost on adherence to prescription medications in Canada.

@en

P1433

Q35761548-0CFB41C0-4317-474A-B0CB-6F77CC2CE38B

P1476

Q35761548-151EE630-6B80-4519-8703-FA2670FBA772

P2093

Q35761548-2B83C3EF-0F39-4A35-974D-6DA573B81FAD

Q35761548-4781334F-D041-49C8-B13C-0DFCE9CF33B5

Q35761548-8E7059F9-C1C4-4E31-BB75-3581E2A5AF95

Q35761548-C342A3CC-66F6-4EC8-AAB8-2374B4D7A72D

Q35761548-EB5017C9-F369-49C5-BA04-B3C7F15C9B86

P2860

Q35761548-04D20A65-FD95-4C40-9352-A6368E05F60F

Q35761548-0F5FBFB8-D78D-4462-AF94-03ECF5F8AFEA

Q35761548-18EA0007-1EBF-4BED-BA1B-18BB69474892

Q35761548-23463101-FFD3-4831-8106-C59FF38860F3

Q35761548-272979BC-52B2-4D57-99E4-D6F8FCFD5288

Q35761548-51A8630B-08EE-42A6-9700-BCB55B76225A

Q35761548-8432C843-80E1-4D37-AF73-727B43B03756

Q35761548-881B7E46-AF44-4798-83C0-07CE7C91D788

Q35761548-9A806E85-82D1-4D5B-AAEE-AEC8691A8762

Q35761548-9D937AB4-C3B9-4D28-A44C-ED1A5309E871

P304

Q35761548-1F1EC4EC-8E7A-46B9-85B8-EED64959E0FE

P31

Q35761548-57F95930-B98E-40D7-B9D8-9BCEABF68BE9

P356

Q35761548-19F79D49-3983-4A38-9596-13D611B44472

P407

Q35761548-DEDF524F-BE1F-47B8-A5AE-A4E8393533BD

P433

Q35761548-E4DE8587-BE99-4F3A-848A-A35F1C6A6D17

P478

Q35761548-DD051006-1C6E-48E8-B1D2-9E43362B7C54

P577

Q35761548-1A4989E3-7C16-4E5D-A01B-2EFF57F7D620

P5875

Q35761548-D92A3B18-66C3-4395-A16A-D80585E40B35

P698

Q35761548-1B0E6FDD-AF4C-4924-B407-AF201BA91460

P921

Q35761548-1C7A4478-6EA4-44CE-B167-5EB61A228F5A

P932

Q35761548-5DCFF55A-1063-4E06-BD7E-BD86FA4B09D7

P356

P1433

Canadian Medical Association Journal

P1476

The effect of cost on adherence to prescription medications in Canada.

@en

P2093

Deborah Heard

http://www.w3.org/2001/XMLSchema#string

Irfan A Dhalla

http://www.w3.org/2001/XMLSchema#string

Lucy Cheng

http://www.w3.org/2001/XMLSchema#string

Michael R Law

http://www.w3.org/2001/XMLSchema#string

Steven G Morgan

http://www.w3.org/2001/XMLSchema#string

P2860

Toward higher-performance health systems: adults' health care experiences in seven countries, 2007

Adherence to Medication

A cross-national study of prescription nonadherence due to cost: data from the Joint Canada-United States Survey of Health.

Costs and benefits of free medications after myocardial infarction.

Revisiting the behavioral model and access to medical care: does it matter?

Effects of prescription drug user fees on drug and health services use and on health status in vulnerable populations: a systematic review of the evidence.

Patients at-risk for cost-related medication nonadherence: a review of the literature.

Prescription drug cost sharing: associations with medication and medical utilization and spending and health.

Cost-related medication nonadherence and spending on basic needs following implementation of Medicare Part D.

Drug coverage in Canada: who is at risk?

P304

297-302

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1503/CMAJ.111270

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

184

http://www.w3.org/2001/XMLSchema#string

P577

2012-01-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221752072

http://www.w3.org/2001/XMLSchema#string

P698

22249979

http://www.w3.org/2001/XMLSchema#string

P921

P932

3281154

http://www.w3.org/2001/XMLSchema#string